Moderna Surges After Historic Phase 3 Success for First mRNA Cancer Therapy
Moderna shares surged after positive Phase 3 results for the first successful mRNA cancer therapy, adding more than $50 billion in market value.
#Healthcare
Explore MarketSpeaker's latest reporting, research, and expert analysis tagged with "healthcare", collected in one continuously updated archive.
Related Posts
Moderna Shares Soar After Personalized mRNA Cancer Vaccine Succeeds in Phase III Trial
Moderna and Merck reported the first successful Phase III trial of a personalized mRNA cancer vaccine, sending Moderna shares sharply higher.
AstraZeneca and Bristol Myers Hold Merger Talks in Potential $400 Billion Deal
AstraZeneca and Bristol Myers Squibb have held discussions about a potential merger valued at more than $400 billion, a deal that would create one of the world’s largest pharmaceutical companies.
Eli Lilly to Acquire Ajax Therapeutics in Deal Worth Up to $2.3 Billion
By
Emma Clarke
• 2 mins read
Eli Lilly will acquire Ajax Therapeutics for up to $2.3 billion, strengthening its pipeline in blood cancer treatments.
Sun Pharma Shares Jump 7% on $11.75 Billion Organon Acquisition
By
Emma Clarke
• 2 mins read
Sun Pharma shares rose 7% after announcing an $11.75 billion deal to acquire U.S.-based Organon, expanding its global footprint.
Novo Nordisk Partners With OpenAI to Accelerate AI-Driven Drug Discovery
By
Emma Clarke
• 3 mins read
Novo Nordisk has partnered with OpenAI to enhance its drug discovery efforts using advanced AI tools, aiming to accelerate identification of new treatments.
Eli Lilly Strikes Up to $2.75 Billion AI Drug Deal With Insilico Medicine
By
Emma Clarke
• 2 mins read
Eli Lilly will pay up to $2.75 billion to bring AI-developed drugs from Insilico Medicine to market. The deal highlights growing momentum in AI-driven drug discovery.
Novartis Acquires Excellergy for $2 Billion in Immunology Push
By
Emma Clarke
• 2 mins read
Novartis has agreed to acquire immunology biotech Excellergy for $2 billion, marking its second major deal in a week. The move strengthens its pipeline in next-generation allergy treatments.
Recursion Pharmaceuticals
By
Emma Clarke
• 3 mins read
Recursion Pharmaceuticals, Inc. is an American clinical-stage biotechnology company that uses automated experiments, biological datasets, computing, and machine learning in drug discovery. It develops its own medicine candidates and conducts research programs with pharmaceutical partners.
Biohacker Bryan Johnson Says Humans Could Achieve Immortality by 2039 Using AI and Radical
By
Benjamin Harper
• 2 mins read
Tech entrepreneur and biohacker Bryan Johnson claims artificial intelligence and experimental medicine could make human immortality achievable within 15 years, despite unresolved risks.
Eli Lilly Becomes First Health-Care Company to Reach $1 Trillion Market Value
By
Oleg Petrenko
• 2 mins read
Eli Lilly crossed a $1 trillion market capitalization for the first time, powered by booming demand for its diabetes and weight-loss drugs.